Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 12/2017

Open Access 01-12-2017 | UROSURGERY (P SOORIAKUMARAN, SECTION EDITOR)

Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer

Author: Aaron Leiblich

Published in: Current Urology Reports | Issue 12/2017

Login to get access

Abstract

Purpose of Review

This review aims to evaluate research surrounding the utility of urinary biomarkers to detect bladder cancer and predict recurrence.

Recent Findings

Recent research has focussed on the evaluation of genetic markers found in urine to provide diagnostic and prognostic information. Furthermore, the isolation and characterisation of extracellular vesicles (EVs) from the urine patients with bladder cancer provide an exciting new development in biomarker research that is set to expand in the coming years.

Summary

Current urinary biomarker research is a broad field that encompasses the evaluation of urinary proteins, DNA, RNA and EVs to detect signatures that can be used to predict the presence of bladder cancer and provide prognostic information. EVs in particular offer an exciting and novel perspective in the search for accurate bladder cancer biomarkers.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–41.CrossRefPubMed
3.
4.
Johnson MI, Merrilees D, Robson WA, et al. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int. 2007;100:826–9.CrossRefPubMed
5.
Burke DM, Shackley DC, O'Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int. 2002;89:347–9.CrossRefPubMed
6.
Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008;53:1138–48.CrossRefPubMed
7.
Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008;101:702–5. discussion 5-6CrossRefPubMed
8.
Biardeau X, Lam O, Ba V, Campeau L, Corcos J. Prospective evaluation of anxiety, pain, and embarrassment associated with cystoscopy and urodynamic testing in clinical practice. Can Urol Assoc J. 2017;11:104–10.CrossRefPubMedPubMedCentral
9.
Giannopoulos A, Manousakas T, Mitropoulos D, et al. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology. 2000;55:871–5.CrossRefPubMed
10.
Gregoire M, Fradet Y, Meyer F, et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol. 1997;157:1660–4.CrossRefPubMed
11.
Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol. 1998;16:17–22.PubMed
12.
Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 1999;161:443–6.CrossRefPubMed
13.
Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161:388–94.CrossRefPubMed
14.
Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 1999;161:62–5.CrossRefPubMed
15.
Renshaw AA, Granter SR. Fine needle aspiration of chromophobe renal cell carcinoma. Acta Cytol. 1996;40:867–72.CrossRefPubMed
16.
Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem. 2000;46:595–605.PubMed
17.
Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116–23.CrossRefPubMedPubMedCentral
18.
Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005;173:401–4.CrossRefPubMed
19.
Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer. 2009;124:2899–904.CrossRefPubMed
20.
Lodde M, Mian C, Mayr R, et al. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. Int J Urol. 2014;21:968–72.CrossRefPubMed
21.
Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013;121:591–7.CrossRefPubMedPubMedCentral
22.
Greene KL, Berry A, Konety BR. Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev Urol. 2006;8:190–7.PubMedPubMedCentral
23.
Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004;22:145–9.CrossRefPubMed
24.
Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study. Can J Urol. 2012;19:6345–50.PubMed
25.
Choi HS, Lee SI, Kim DJ, Jeong TY. Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer. Korean J Urol. 2010;51:88–93.CrossRefPubMedPubMedCentral
26.
Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ. Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol. 2012;30:869–73.CrossRefPubMedPubMedCentral
27.
Shariat SF, Marberger MJ, Lotan Y, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol. 2006;176:919–26. discussion 26CrossRefPubMed
28.
Rosser CJ, Chang M, Dai Y, et al. Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomark Prev. 2014;23:1340–5.CrossRef
29.
Sanchez-Carbayo M, Herrero E, Megias J, et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol. 1999;161:1110–5.CrossRefPubMed
30.
Ritter R, Hennenlotter J, Kuhs U, et al. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol. 2014;32:337–44.CrossRefPubMed
31.
Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007;17:341–6.CrossRefPubMed
32.
Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol. 2005;174:64–8.CrossRefPubMed
33.
Konety BR, Nguyen TS, Dhir R, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000;6:2618–25.PubMed
34.
Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology. 2005;66:1256–60.CrossRefPubMed
35.
Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res. 2004;10:1384–91.CrossRefPubMed
36.
Konety BR, Nguyen TS, Brenes G, et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol. 2000;164:634–9.CrossRefPubMed
37.
Santoni M, Catanzariti F, Minardi D, et al. Pathogenic and diagnostic potential of BLCA-1 and BLCA-4 nuclear proteins in urothelial cell carcinoma of human bladder. Adv Urol. 2012;2012:397412.CrossRefPubMedPubMedCentral
38.
39.
van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912–21.CrossRefPubMed
40.
Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–9.CrossRefPubMedPubMedCentral
41.
Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24:5218–25.CrossRefPubMed
42.
Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008–17.CrossRefPubMed
43.
Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16:3011–8.CrossRefPubMed
44.
van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (cost-effectiveness of follow-up of urinary bladder cancer trial [CEFUB]). Eur Urol. 2009;55:659–67.CrossRefPubMed
45.
46.
Chung W, Bondaruk J, Jelinek J, et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomark Prev. 2011;20:1483–91.CrossRef
47.
Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011;17:5582–92.CrossRefPubMed
48.
Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol. 2013;10:327–35.CrossRefPubMed
49.
Zhao Y, Guo S, Sun J, et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One. 2012;7:e35175.CrossRefPubMedPubMedCentral
50.
Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004;171:626–30.CrossRefPubMed
51.
Horstmann M, Bontrup H, Hennenlotter J, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol. 2010;28:399–404.CrossRefPubMed
52.
Srivastava AK, Singh PK, Srivastava K, et al. Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev. 2013;14:81–5.CrossRefPubMed
53.
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836–48.CrossRefPubMed
54.
Liang LG, Kong MQ, Zhou S, et al. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. Sci Rep. 2017;7:46224.CrossRefPubMedPubMedCentral
55.
56.
Lin SCCW, Lin C, Chang K, Yang C, Huang C, Hsu W, et al. Proteome profiling of urinary exosomes identifies alpha 1-antitrypsin and H2B1K as diagnostic and prognostic biomarkers for urothelial carcinoma. Sci Rep. 2016;6:12.CrossRef
57.
Berrondo C, Flax J, Kucherov V, et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One. 2016;11:e0147236.CrossRefPubMedPubMedCentral
58.
Andreu Z, Otta Oshiro R, Redruello A, et al. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression. Eur J Pharm Sci. 2017;98:70–9.CrossRefPubMed
Metadata
Title
Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer
Author
Aaron Leiblich
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Urology Reports / Issue 12/2017
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-017-0748-x

Other articles of this Issue 12/2017

Current Urology Reports 12/2017 Go to the issue

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

New Devices and Technologies for the Management of Overactive Bladder

Urosurgery (P Sooriakumaran, Section Editor)

Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy

New Imaging Techniques (S Rais-Bahrami and A George, Section Editors)

Predictability and Practicality of Image-Based Scoring Systems for Patient Assessment and Outcome Stratification During Percutaneous Nephrolithotomy: a Contemporary Update

New Imaging Techniques (S Rais-Bahrami and A George, Section Editors)

HistoScanningTM to Detect and Characterize Prostate Cancer—a Review of Existing Literature

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes

Pediatric Urology (D Weiss, Section Editor)

Ureteroscopy for Stone Disease in Paediatric Population is Safe and Effective in Medium-Volume and High-Volume Centres: Evidence from a Systematic Review